Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
abbvie
8
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
biotech
new york blog main
new york top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
eli lilly
merck
pfizer
startups
alzheimer's disease
astrazeneca
bristol-myers squibb
cancer
cancer immunotherapy
deals
medicare
What
drug
8
×
bio
roundup
fda
treatment
acquisitions
approved
biggest
ceo
companies
disease
nash
new
news
patients
prices
today
week
acorda
albert
alkermes
alzheimer’s
annual
antipsychotic
approval
assessed
attention
away
benefits
biogen’s
biopharmaceutical
biotech
bourla
bringing
build
buy
caveats
ceos
commonly
communities
Language
unset
unknown
Current search:
abbvie
×
drug
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More